Advanced Vaccine Laboratories

Advanced Vaccine Laboratories Pty Ltd (AVL) is an Australian biotechnology company and a subsidiary of Advaccine Biopharmaceuticals Suzhou Co., Ltd. The company was established to facilitate the clinical development of Advaccine's vaccine candidates in Australia, with a primary focus on its lead program, BARS13 (also known as ADV110). BARS13 is a recombinant Respiratory Syncytial Virus (RSV) vaccine that targets the RSV-G protein and utilizes cyclosporine A as an immunomodulator to enhance safety and immunogenicity. AVL has successfully completed a Phase 1 first-in-human study and is currently conducting Phase 2 clinical trials in healthy older adults to evaluate the vaccine's safety and tolerability. The company's approach is unique in targeting the G protein, which aims to prevent both viral infection and cell-to-cell fusion spread. AVL operates out of Melbourne, Victoria, and serves as a key clinical arm for its parent company's global vaccine pipeline.